Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Achalasia in a Patient Undergoing Hematologic Stem Cell Transplant After Exposure to Tacrolimus.

Goklemez S, Curtis LM, Hawwa A, Ling A, Avila D, Heller T, Pavletic SZ.

Mayo Clin Proc Innov Qual Outcomes. 2017 Aug 2;1(2):198-201. doi: 10.1016/j.mayocpiqo.2017.06.004. eCollection 2017 Sep.

2.

Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients.

Kerep AZ, Broome J, Pirsl F, Curtis LM, Steinberg SM, Mitchell SA, Cowen EW, Pichard DC, Joe GO, Comis LE, Mays JW, Datiles MB 3rd, Stratton P, Zolton J, Berger A, Hendricks J, Kenyon M, Baruffaldi J, Titarenko I, Pulanic D, Baird K, Fowler DH, Gress RE, Pavletic SZ.

Bone Marrow Transplant. 2018 Aug 8. doi: 10.1038/s41409-018-0224-3. [Epub ahead of print]

PMID:
30089900
3.

Amniotic membrane transplantation-a new approach to crossing the HLA barriers in the treatment of refractory ocular graft-versus-host disease.

Peric Z, Skegro I, Durakovic N, Desnica L, Pulanic D, Serventi-Seiwerth R, Petricek I, Pavletic SZ, Vrhovac R.

Bone Marrow Transplant. 2018 Aug 8. doi: 10.1038/s41409-018-0140-6. [Epub ahead of print] No abstract available.

PMID:
30089899
4.

Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally.

Hakim A, Cooke KR, Pavletic SZ, Khalid M, Williams KM, Hashmi SK.

Bone Marrow Transplant. 2018 Jul 23. doi: 10.1038/s41409-018-0266-6. [Epub ahead of print] Review.

PMID:
30038355
5.

A phase II/III randomized, multicenter trial of Prednisone /Sirolimus vs Prednisone/Sirolimus/Calcineurin Inhibitor for treatment of chronic graft-versus-host disease: BMT CTN 0801.

Carpenter PA, Logan BR, Lee SJ, Weisdorf DJ, Johnston L, Costa LJ, Kitko CL, Bolaños-Meade J, Sarantopoulos S, Alousi AM, Abhyankar S, Waller EK, Mendizabal A, Zhu J, O'Brien KA, Lazaryan A, Wu J, Nemecek ER, Pavletic SZ, Cutler CS, Horowitz MM, Arora M; Blood and Marrow Clinical Trials Network.

Haematologica. 2018 Jun 28. pii: haematol.2018.195123. doi: 10.3324/haematol.2018.195123. [Epub ahead of print]

6.

The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial.

Schoemans HM, Goris K, Van Durm R, Fieuws S, De Geest S, Pavletic SZ, Im A, Wolff D, Lee SJ, Greinix H, Duarte RF, Poiré X, Selleslag D, Lewalle P, Kerre T, Graux C, Baron F, Maertens JA, Dobbels F; EBMT Transplantation Complications Working party.

Haematologica. 2018 Oct;103(10):1698-1707. doi: 10.3324/haematol.2018.190777. Epub 2018 Jun 14.

7.

EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment.

Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, Shaw BE, Flowers ME, Ruutu T, Greinix H, Holler E, Basak G, Duarte RF, Pavletic SZ; EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the “EBMT−NIH (National Institutes of Health)−CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force”.

Bone Marrow Transplant. 2018 Jun 5. doi: 10.1038/s41409-018-0204-7. [Epub ahead of print] No abstract available.

PMID:
29872128
8.

Introduction to a review series on emerging immunotherapies for hematologic diseases.

Paczesny S, Pavletic SZ, Bollard CM.

Blood. 2018 Jun 14;131(24):2617-2620. doi: 10.1182/blood-2018-04-840793. Epub 2018 May 4. Review.

9.

Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis.

Yalniz FF, Murad MH, Lee SJ, Pavletic SZ, Khera N, Shah ND, Hashmi SK.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1920-1927. doi: 10.1016/j.bbmt.2018.03.008. Epub 2018 Mar 14.

PMID:
29550629
10.

Autologous blood as a source of platelet gel for the effective and safe treatment of oral chronic graft-versus-host disease.

Bojanic I, Mravak Stipetic M, Pulanic D, Desnica L, Mazic S, Golubic Cepulic B, Serventi Seiwerth R, Vrhovac R, Nemet D, Pavletic SZ.

Transfusion. 2018 Jun;58(6):1494-1499. doi: 10.1111/trf.14594. Epub 2018 Mar 14.

PMID:
29542126
11.

Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease.

Buxbaum NP, Robinson C, Sinaii N, Ling A, Curtis LM, Pavletic SZ, Baird K, Lodish MB.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1415-1423. doi: 10.1016/j.bbmt.2018.02.019. Epub 2018 Mar 1.

PMID:
29496562
12.

Accuracy and usability of the eGVHD app in assessing the severity of graft-versus-host disease at the 2017 EBMT annual congress.

Schoemans HM, Goris K, Van Durm R, Vanbrabant K, De Geest S, Maertens J, Wolff D, Greinix H, Ruutu T, Pavletic SZ, Im A, Lee SJ, Basak GW, Duarte RF, Dobbels F; Complications and Quality of Life Working Party of the EBMT.

Bone Marrow Transplant. 2018 Apr;53(4):490-494. doi: 10.1038/s41409-017-0017-0. Epub 2018 Jan 12. No abstract available.

PMID:
29330389
13.

An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.

Poe JC, Jia W, Su H, Anand S, Rose JJ, Tata PV, Suthers AN, Jones CD, Kuan PF, Vincent BG, Serody JS, Horwitz ME, Ho VT, Pavletic SZ, Hakim FT, Owzar K, Zhang D, Blazar BR, Siebel CW, Chao NJ, Maillard I, Sarantopoulos S.

Blood. 2017 Nov 9;130(19):2131-2145. doi: 10.1182/blood-2017-05-782466. Epub 2017 Aug 29.

PMID:
28851699
14.

Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients.

Curtis LM, Pirsl F, Steinberg SM, Mitchell SA, Baird K, Cowen EW, Mays J, Buxbaum NP, Pichard DC, Im A, Avila D, Taylor T, Fowler DH, Gress RE, Pavletic SZ.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1980-1988. doi: 10.1016/j.bbmt.2017.08.005. Epub 2017 Aug 7.

PMID:
28797782
15.

Clinical significance of IgE in a large cohort of patients with moderate or severe chronic graft-versus-host disease.

Goklemez S, Pirsl F, Curtis LM, Steinberg SM, Cowen EW, Mays JW, Kenyon M, Baruffaldi J, Hakim FT, Pavletic SZ.

Am J Hematol. 2017 Aug;92(8):E162-E164. doi: 10.1002/ajh.24768. Epub 2017 Jun 1. No abstract available.

16.

Immunotherapy in hematologic malignancies: past, present, and future.

Im A, Pavletic SZ.

J Hematol Oncol. 2017 Apr 24;10(1):94. doi: 10.1186/s13045-017-0453-8. Review.

17.

Novel targets in the treatment of chronic graft-versus-host disease.

Im A, Hakim FT, Pavletic SZ.

Leukemia. 2017 Mar;31(3):543-554. doi: 10.1038/leu.2016.367. Epub 2016 Nov 30. Review.

PMID:
27899803
18.

High prevalence of small- and large-fiber neuropathy in a prospective cohort of patients with moderate to severe chronic GvHD.

Bilic E, Delimar V, Desnica L, Pulanic D, Bilic E, Bakovic M, Curtis LM, Seiwerth RS, Stipetic MM, Ceovic R, Pulanic TK, Aleric I, Milos O, Vrhovac R, Nemet D, Pavletic SZ.

Bone Marrow Transplant. 2016 Nov;51(11):1513-1517. doi: 10.1038/bmt.2016.158. Epub 2016 Jun 6. No abstract available.

PMID:
27272447
19.

Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2117-2125. doi: 10.1016/j.bbmt.2016.09.013. Epub 2016 Sep 19. Review.

20.

Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.

Hakim FT, Memon S, Jin P, Imanguli MM, Wang H, Rehman N, Yan XY, Rose J, Mays JW, Dhamala S, Kapoor V, Telford W, Dickinson J, Davis S, Halverson D, Naik HB, Baird K, Fowler D, Stroncek D, Cowen EW, Pavletic SZ, Gress RE.

J Immunol. 2016 Nov 1;197(9):3490-3503. Epub 2016 Sep 30.

21.

Umbilical Cord Blood-Derived Mesenchymal Stromal Cells for Reducing Chronic Graft-Versus-Host Disease After Haploidentical Transplantation: Just Another Labor-Intensive Strategy, or Showing the Way?

Lazarus HM, Pavletic SZ.

J Clin Oncol. 2016 Aug 20;34(24):2812-3. doi: 10.1200/JCO.2016.67.7344. Epub 2016 Jul 11. No abstract available.

PMID:
27400943
22.

IL-2, the next best thing in chronic GVHD therapy?

Curtis LM, Pavletic SZ.

Blood. 2016 Jul 7;128(1):13-5. doi: 10.1182/blood-2016-05-711796. No abstract available.

23.

Vitamin D levels and their associations with survival and major disease outcomes in a large cohort of patients with chronic graft-vs-host disease.

Katić M, Pirsl F, Steinberg SM, Dobbin M, Curtis LM, Pulanić D, Desnica L, Titarenko I, Pavletic SZ.

Croat Med J. 2016 Jun 30;57(3):276-86.

24.

Joint and fascial chronic graft-vs-host disease: correlations with clinical and laboratory parameters.

Vukić T, Robinson Smith S, Ljubas Kelečić D, Desnica L, Prenc E, Pulanić D, Vrhovac R, Nemet D, Pavletic SZ.

Croat Med J. 2016 Jun 30;57(3):266-75.

25.

Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity?

Duraković N, Krečak I, Perić Z, Milošević M, Desnica L, Pulanić D, Pusic I, Kušec V, Vrhovac R, Pavletic SZ, Nemet D.

Croat Med J. 2016 Jun 30;57(3):239-46.

26.

High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease.

Čeović R, Desnica L, Pulanić D, Serventi Seiwerth R, Ilić I, Grce M, Mravak Stipetić M, Klepac Pulanić T, Bilić E, Bilić E, Milošević M, Vrhovac R, Nemet D, Pavletic SZ.

Croat Med J. 2016 Jun 30;57(3):229-38.

27.

Erratum to "Salivary Gland Involvement in Chronic Graft-versus-Host Disease: Prevalence, Clinical Significance, and Recommendations for Evaluation" [Biol Blood Marrow Transplant 16:1362-1369].

Imanguli MM, Atkinson JC, Mitchell SA, Avila DN, Bishop RJ, Cowen EW, Datiles MB, Hakim FT, Kleiner DE, Krumlauf MC, Pavletic SZ.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1147. doi: 10.1016/j.bbmt.2015.09.026. Epub 2015 Oct 9. No abstract available.

28.

Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease.

Pirsl F, Curtis LM, Steinberg SM, Tella SH, Katić M, Dobbin M, Hsu J, Hakim FT, Mays JW, Im AP, Pulanić D, Mitchell SA, Baruffaldi J, Masuch L, Halverson DC, Gress RE, Barsony J, Pavletic SZ.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1517-1524. doi: 10.1016/j.bbmt.2016.04.012. Epub 2016 Apr 23.

29.

Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease?

Perić Z, Desnica L, Duraković N, Ostojić A, Pulanić D, Serventi-Seiwerth R, Prenc E, Basak G, Vrhovac R, Pavletic SZ, Nemet D.

Croat Med J. 2016 Feb;57(1):6-15.

30.

Chronic graft-vs-host disease in 2016: a major challenge and an opportunity.

Pulanić D, Desnica L, Vrhovac R, Nemet D, Wolff D, Greinix H, Pavletic SZ.

Croat Med J. 2016 Feb;57(1):1-3. No abstract available.

31.

Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation.

Prenc E, Pulanic D, Pucic-Bakovic M, Pezer M, Desnica L, Vrhovac R, Nemet D, Pavletic SZ.

Biochim Biophys Acta. 2016 Aug;1860(8):1615-22. doi: 10.1016/j.bbagen.2016.02.015. Epub 2016 Feb 26. Review.

32.

Prevalence and determinants of fatigue in patients with moderate to severe chronic GvHD.

Im A, Mitchell SA, Steinberg SM, Curtis L, Berger A, Baird K, Kuzmina Z, Joe G, Comis LE, Juckett M, Avila D, Baruffaldi J, Masuch L, Pirsl F, Pavletic SZ.

Bone Marrow Transplant. 2016 May;51(5):705-12. doi: 10.1038/bmt.2015.320. Epub 2016 Feb 1.

PMID:
26828906
33.

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, Gea-Banacloche JC, Pavletic SZ, Hickstein DD, Lu TL, Feldman SA, Iwamoto AT, Kurlander R, Maric I, Goy A, Hansen BG, Wilder JS, Blacklock-Schuver B, Hakim FT, Rosenberg SA, Gress RE, Kochenderfer JN.

J Clin Oncol. 2016 Apr 1;34(10):1112-21. doi: 10.1200/JCO.2015.64.5929. Epub 2016 Jan 25.

34.

Phase-1/-2 study of pomalidomide in chronic GvHD.

Pusic I, Rettig MP, DiPersio JF, Bauer S, McFarland K, Gale RP, Pavletic SZ.

Bone Marrow Transplant. 2016 Apr;51(4):612-4. doi: 10.1038/bmt.2015.298. Epub 2015 Dec 14. No abstract available.

PMID:
26657832
35.

Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease.

Palmer J, Chai X, Pidala J, Inamoto Y, Martin PJ, Storer B, Pusic I, Flowers ME, Arora M, Pavletic SZ, Lee SJ.

Blood. 2016 Jan 7;127(1):160-6. doi: 10.1182/blood-2015-08-662874. Epub 2015 Nov 2.

36.

Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.

Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S, Chien JW, Jacobsohn DA, Pavletic SZ, Martin PJ, Storer BE, Inamoto Y, Chai X, Flowers MED, Lee SJ.

Biol Blood Marrow Transplant. 2016 Apr;22(4):710-716. doi: 10.1016/j.bbmt.2015.10.009. Epub 2015 Oct 22.

37.

Deciphering the Mystery: Extracorporeal Photopheresis in Graft-versus-Host Disease.

Im A, Pavletic SZ.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1861-2. doi: 10.1016/j.bbmt.2015.09.011. Epub 2015 Sep 18. No abstract available.

38.

Immunotherapy for acute leukemia.

Boyiadzis M, Whiteside TL, Pavletic SZ.

Aging (Albany NY). 2015 Jun;7(6):354-5. No abstract available.

39.

Syk and tired of current chronic GVHD therapies.

Fowler DH, Pavletic SZ.

Blood. 2015 Jun 25;125(26):3974-5. doi: 10.1182/blood-2015-05-640672.

40.

Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice.

Curtis LM, Datiles MB 3rd, Steinberg SM, Mitchell SA, Bishop RJ, Cowen EW, Mays J, McCarty JM, Kuzmina Z, Pirsl F, Fowler DH, Gress RE, Pavletic SZ.

Haematologica. 2015 Sep;100(9):1228-36. doi: 10.3324/haematol.2015.124131. Epub 2015 Jun 18.

41.

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.

Mossoba ME, Halverson DC, Kurlander R, Schuver BB, Carpenter A, Hansen B, Steinberg SM, Ali SA, Tageja N, Hakim FT, Gea-Banacloche J, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Khuu H, Sabatini M, Stroncek D, Levine BL, June CH, Mariotti J, Rixe O, Fojo AT, Bishop MR, Gress RE, Fowler DH.

Clin Cancer Res. 2015 Oct 1;21(19):4312-20. doi: 10.1158/1078-0432.CCR-15-0340. Epub 2015 Jun 12.

42.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report.

Martin PJ, Lee SJ, Przepiorka D, Horowitz MM, Koreth J, Vogelsang GB, Walker I, Carpenter PA, Griffith LM, Akpek G, Mohty M, Wolff D, Pavletic SZ, Cutler CS.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1343-59. doi: 10.1016/j.bbmt.2015.05.004. Epub 2015 May 15. Review.

43.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.

Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J, Montoto S, Perales MA, Aljurf MD, Akpek G, Bredeson CN, Costa LJ, Dandoy C, Freytes CO, Fung HC, Gale RP, Gibson J, Hamadani M, Hayashi RJ, Inamoto Y, Inwards DJ, Lazarus HM, Maloney DG, Martino R, Munker R, Nishihori T, Olsson RF, Rizzieri DA, Reshef R, Saad A, Savani BN, Schouten HC, Smith SM, Socié G, Wirk B, Yu LC, Saber W.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1746-53. doi: 10.1016/j.bbmt.2015.05.010. Epub 2015 May 15.

44.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.

Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP, Hoodin F, Johnston L, Lawitschka A, McDonald GB, Opipari AW, Savani BN, Schultz KR, Smith SR, Syrjala KL, Treister N, Vogelsang GB, Williams KM, Pavletic SZ, Martin PJ, Lee SJ, Couriel DR.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1167-87. doi: 10.1016/j.bbmt.2015.03.024. Epub 2015 Mar 31.

45.

Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.

Baird K, Comis LE, Joe GO, Steinberg SM, Hakim FT, Rose JJ, Mitchell SA, Pavletic SZ, Figg WD, Yao L, Flanders KC, Takebe N, Sarantopoulos S, Booher S, Cowen EW.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1083-90. doi: 10.1016/j.bbmt.2015.03.006. Epub 2015 Mar 12.

46.

Oral disease profiles in chronic graft versus host disease.

Bassim CW, Fassil H, Mays JW, Edwards D, Baird K, Steinberg SM, Cowen EW, Naik H, Datiles M, Stratton P, Gress RE, Pavletic SZ.

J Dent Res. 2015 Apr;94(4):547-54. doi: 10.1177/0022034515570942. Epub 2015 Mar 4.

47.

NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Shulman HM, Cardona DM, Greenson JK, Hingorani S, Horn T, Huber E, Kreft A, Longerich T, Morton T, Myerson D, Prieto VG, Rosenberg A, Treister N, Washington K, Ziemer M, Pavletic SZ, Lee SJ, Flowers ME, Schultz KR, Jagasia M, Martin PJ, Vogelsang GB, Kleiner DE.

Biol Blood Marrow Transplant. 2015 Apr;21(4):589-603. doi: 10.1016/j.bbmt.2014.12.031. Epub 2015 Jan 29.

48.

2014 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: preface to the series.

Pavletic SZ, Vogelsang GB, Lee SJ.

Biol Blood Marrow Transplant. 2015 Mar;21(3):387-8. doi: 10.1016/j.bbmt.2014.12.035. Epub 2015 Jan 5. No abstract available.

49.

Extracorporeal photopheresis as a therapy for autoimmune diseases.

Kuzmina Z, Stroncek D, Pavletic SZ.

J Clin Apher. 2015 Aug;30(4):224-37. doi: 10.1002/jca.21367. Epub 2014 Dec 26. Review.

PMID:
25546289
50.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME.

Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1. doi: 10.1016/j.bbmt.2014.12.001. Epub 2014 Dec 18.

Supplemental Content

Loading ...
Support Center